FDA Approves Relatlimab Plus Nivolumab for Unresectable or Metastatic Melanoma

Source: Targeted Oncology, March 2022

The FDA has granted approval to the fixed-dose combination of relatlimab plus nivolumab (Opdualag) for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma, according to an announcement by Bristol Myers Squibb.1

The FDA’s decision to approve the combination is based on findings from the hase 2/3 RELATIVITY-047 trial (NCT03470922), in which relatlimab plus nivolumab demonstrated a 22% reduction in risk of progression or death and numerically improved overall survival rates compared to nivolumab alone, according to results presented during the recent ASCO Plenary Series: March 2022 Session.